Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ILQ
|
|||
| Former ID |
DAP001481
|
|||
| Drug Name |
Guanfacine extended release
|
|||
| Synonyms |
Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Impulsin; Palmitamide MEA; Hydroxyethylpalmitamide; N-palmitoylethanolamine; N-(2-Hydroxyethyl)palmitamide; Palmitic acid monoethanolamide; Palmitoyl-EA; Loramine P 256; Palmitoyl ethanolamide; Palmidrolum; palmitylethanolamide; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; Palmidrolum [INN-Latin]; UNII-6R8T1UDM3V; Palmitinsaeure-beta-hydroxyethylamid; Monoethanolamine palmitic acid amide; NSC 23320; hexadecanoyl ethanolamide; Anandamide (16:0)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Approved | [1] | |
| Company |
Shire
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H37NO2
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCC(=O)NCCO
|
|||
| InChI |
1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
|
|||
| InChIKey |
HXYVTAGFYLMHSO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 544-31-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
85235, 6752159, 7850592, 8152869, 11111603, 11113754, 11120210, 11120698, 11121186, 11121519, 11121999, 11147293, 11362588, 11365150, 11367712, 11370447, 11370448, 11373313, 11375874, 14825223, 17405463, 24278619, 26751935, 26751936, 26751937, 29223759, 47290911, 47662029, 47885184, 49661772, 49681174, 50064896, 50104611, 50104612, 50104613, 53778011, 56365485, 56463464, 57309612, 57322388, 77768141, 81054512, 85231178, 90341052, 91053556, 92304274, 92309870, 96025015, 99300784, 99302302
|
|||
| ChEBI ID |
CHEBI:71464
|
|||
| SuperDrug ATC ID |
C02AC02
|
|||
| SuperDrug CAS ID |
cas=029110472
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor Alpha-2 (ADRA2) | Target Info | Agonist | [1] |
| Cannabinoid receptor 2 (CB2) | Target Info | Agonist | [2] | |
| G-protein coupled receptor 55 (GPR55) | Target Info | Agonist | [3] | |
| Glucose-dependent insulinotropic receptor (GPR119) | Target Info | Agonist | [4] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Insulin secretion | ||||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Incretin Synthesis, Secretion, and Inactivation | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Small Ligand GPCRs | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. | |||
| REF 2 | Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81. | |||
| REF 3 | The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.